Ines Semendric

Dr. Ines Semendric

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 August 2023 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
ISInes Semendric
Ines Semendric
DPDanielle Pollock
Danielle Pollock
OHOlivia J. Haller
Olivia J. Haller
RGRebecca P. George
Rebecca P. George
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
Purpose: To examine children’s experiences of chemotherapy-induced cognitive impairment––colloquially “chemobrain”––and the impact on children’s social, academic, and daily living skills via a qualitative systematic review. Experiencing chemotherapy as a child, when the brain is still developing, may cause lifelong detriment to survivors’ lives. There is a significant gap in understanding their lived experience, including the self-identified barriers that children face following treatment. Such a gap can only be fully bridged by listening to the child’s own voice and/or parent proxy report through an exploration of the qualitative research literature. Methods: A search of MEDLINE, Embase, PsycINFO, and CINAHL databases was conducted. Inclusion criteria were qualitative studies with a focus on children (0–18 years) during and/or following chemotherapy treatment and explored children’s experiences of chemobrain. Results: Two synthesized findings were identified from six studies. (1) Chemobrain has an academic and psychosocial impact, which may not be understood by education providers. (2) Children and their parents have concerns about their reintegration and adaptation to school, social lives, and their future selves as independent members of society. Children’s experiences primarily related to changes in their academic and social functioning. Conclusion: This review highlights two important considerations: (1) the lived experiences of pediatric childhood cancer survivors guiding where future interventions should be targeted, and (2) a need to perform more qualitative research studies in this area, as well as to improve the quality of reporting among the existing literature, given that this is a current gap in the field.

12 January 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
ADAdriana Domínguez-Oliva
Adriana Domínguez-Oliva
Daniel Mota-RojasDaniel Mota-Rojas
Daniel Mota-Rojas
ISInes Semendric
Ines Semendric
Alex WhittakerAlex Whittaker
Alex Whittaker
There has been an increase in vegetarianism and veganism in human populations. This trend also appears to be occurring in companion animals, with guardians preferring to feed their animals in accordance with their own dietary values and choices. However, there has been controversy amongst vets and online commentators about the safety of feeding vegan diets to carnivorous species, such as cats and dogs. In spite of this controversy, to date there has been no systematic evaluation of the evidence on this topic. A systematic search of Medline, Scopus, and Web of Science was performed, identifying 16 studies on the impact of vegan diets on cat and dog health. Studies were appraised for quality using established critical appraisal tools or reporting guidelines. There was considerable heterogeneity in the outcomes measured, and study designs employed, with few studies evaluating key outcomes of interest. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was utilized for assessment of certainty in the evidence, with the evidence for most outcomes being assessed as low or very low. Whilst the quality and amount of evidence needs to be considered in formulating recommendations, there was no overwhelming evidence of adverse effects arising from use of these diets and there was some evidence of benefits. It is, however, recommended that future high-quality studies, with standardized outcome measures and large sample sizes, be conducted. At the current time, if guardians wish to feed their companion animals vegan diets, a cautious approach should be taken using commercially produced diets which have been formulated considering the nutritional needs of the target species.

15 July 2025 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
ISInes Semendric
Ines Semendric
TBTimothy H. Barker
Timothy H. Barker
OHOlivia J. Haller
Olivia J. Haller
DPDanielle Pollock
Danielle Pollock
LCLyndsey E. Collins-Praino
Lyndsey E. Collins-Praino
AWAlexandra L. Whittaker
Alexandra L. Whittaker
Neurocognitive toxicity is a common sequela of cancer and its treatment, with 40-60 % of childhood cancer survivors experiencing cancer-related cognitive impairment (CRCI) following cancer. CNS cancers and CNS-directed therapy are considered to pose the greatest risk; however, such impairment has also been reported in non-CNS cancers, the most commonly diagnosed in children. Despite initial findings, no formal systematic assimilation of evidence has previously reported estimates in pediatric populations, or identified the influence of cancer, treatment, and patient variables. Thus, this review aims to investigate the prevalence of CRCI in pediatric non-CNS cancers. A systematic search was conducted (21/04/2023 and updated 08/2024) using PubMed via MEDLINE, Scopus, PsycINFO via OvidSP, and CINAHL via EBSCOhost. Simple proportional meta-analyses were performed using PERSyst, and certainty of evidence was assessed employing GRADE. Twenty-six studies contributed to two categories - (1) cognitive function and intelligence, and (2) achievement, aptitude and school readiness. Pooled prevalence estimates suggest that survivors of non-CNS cancers experience impairments in intelligence (12.46 %-18.05 %) and attention (9.83 %-12.05 %). Non-pooled prevalence estimates ranged from 0 % to 67 % in cognitive function and intelligence, with effects on executive function (2 %-42.8 %), learning and memory (4.7 %-57 %), visuo-spatial/perceptual motor (3 %-61.9 %), and language (4 %-37 %), and 0-73 % in achievement, aptitude and school readiness. Survivors of non-CNS cancers experience significant impairments in these categories; however, certainty of evidence is generally low to very low, warranting cautious interpretation of prevalence estimates. Understanding the prevalence of CRCI can inform survivorship strategies and provide impetus for dedicated supports, such as rehabilitation and school reintegration.

9 March 2023 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
OHOlivia J. Haller
Olivia J. Haller
ISInes Semendric
Ines Semendric
RGRebecca P. George
Rebecca P. George
LCLyndsey E. Collins-Praino
Lyndsey E. Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
Chemotherapy-induced cognitive impairment (CICI) is a debilitating condition resulting from chemotherapy administration for cancer treatment. CICI is characterised by various cognitive impairments, including issues with learning, memory, and concentration, impacting quality of life. Several neural mechanisms are proposed to drive CICI, including inflammation, therefore, anti-inflammatory agents could ameliorate such impairments. Research is still in the preclinical stage; however, the efficacy of anti-inflammatories to reduce CICI in animal models is unknown. Therefore, a systematic review was conducted, with searches performed in PubMed, Scopus, Embase, PsycInfo and Cochrane Library. A total of 64 studies were included, and of the 50 agents identified, 41 (82%) reduced CICI. Interestingly, while non-traditional anti-inflammatory agents and natural compounds reduced impairment, the traditional agents were unsuccessful. Such results must be taken with caution due to the heterogeneity observed in terms of methods employed. Nevertheless, preliminary evidence suggests anti-inflammatory agents could be beneficial for treating CICI, although it may be critical to think beyond the use of traditional anti-inflammatories when considering which specific compounds to prioritise in development.

2 August 2021 in JBI Evidence Synthesis
Verified
Journal Article
Closed access
ISInes Semendric
Ines Semendric
DPDanielle Pollock
Danielle Pollock
OHOlivia J. Haller
Olivia J. Haller
RGRebecca P. George
Rebecca P. George
LCLyndsey E Collins-Praino
Lyndsey E Collins-Praino
Alex WhittakerAlex Whittaker
Alex Whittaker
Objective: The objective of this review is to examine children's experiences of chemotherapy-induced cognitive impairment (also known as “chemobrain”) and the impact of chemobrain on children's social, academic, and daily living skills. Introduction: The effect of childhood chemotherapy treatment on cognition is of concern because of the vulnerable nature of children's developing brains and the potential to cause lifelong detriments socially, academically, and economically. Furthermore, this population is under-represented in the chemobrain literature and in survivorship care plans. As cancer survivorship among this group increases, it is important to understand childhood experiences so that rehabilitation strategies and suitable supports can be put in place. Inclusion criteria: This review of qualitative studies will focus on the pediatric population (0 to 18 years of age) during and/or following chemotherapy treatment to identify their experiences with chemobrain. The review will include any studies using a qualitative research methodology (eg, surveys, focus groups, interview transcripts), conducted in any geographic location, where experiences are presented from the child's perspective. Studies assessing children's experiences of cancer, other chemotherapy-related side effects, or the parent's personal experience will be excluded. Methods: A search of MEDLINE, Embase, PsycINFO, and CINAHL databases will be conducted. Full-text, English-only articles employing a qualitative research methodology will be included in the screening process. Two independent reviewers will retrieve and screen full-text studies, and assess methodological quality of the included studies. Meta-aggregation will be performed and a ConQual Summary of Findings will present the confidence in the findings. Systematic review registration number: PROSPERO CRD42021240573.